• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡巴他赛通过抑制去势抵抗性前列腺癌中的Sestrin-3诱导活性氧生成

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.

作者信息

Kosaka Takeo, Hongo Hiroshi, Miyazaki Yasumasa, Nishimoto Koshiro, Miyajima Akira, Oya Mototsugu

机构信息

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.

出版信息

Oncotarget. 2017 Sep 21;8(50):87675-87683. doi: 10.18632/oncotarget.21147. eCollection 2017 Oct 20.

DOI:10.18632/oncotarget.21147
PMID:29152111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5675663/
Abstract

Reactive oxygen species (ROS) production induced by taxanes in cancer cells may influence the taxane-induced cell death or the drug resistance. We investigated the correlation between the cytotoxic effect of taxanes and ROS production in human castration-resistant prostate cancer (CRPC) cell lines. Three human prostate cancer cell lines were treated with increasing concentrations of docetaxel or cabazitaxel . Cabazitaxel showed significantly higher cytotoxic efficacy than docetaxel in human CRPC cells, accompanied by elevated ROS production detected by FACS analysis. To investigate whether cabazitaxel-mediated cell death was caused by the ROS generation induced by cabazitaxel, we treated CRPC cells in the presence of antioxidant NAC. NAC reduced the cytotoxic effect induced by cabazitaxel. We found that ROS elimination by Sestrin-3 () was significantly inhibited by cabazitaxel, but not by docetaxel. These results indicate higher sensitivity of human CRPC to cabazitaxel compared to docetaxel involves ROS production through inhibiting the expression of antioxidant enzyme SESN3.

摘要

紫杉烷在癌细胞中诱导产生的活性氧(ROS)可能会影响紫杉烷诱导的细胞死亡或耐药性。我们研究了紫杉烷的细胞毒性作用与人类去势抵抗性前列腺癌(CRPC)细胞系中ROS产生之间的相关性。用递增浓度的多西他赛或卡巴他赛处理三种人类前列腺癌细胞系。在人类CRPC细胞中,卡巴他赛显示出比多西他赛显著更高的细胞毒性效力,同时通过流式细胞术分析检测到ROS产生增加。为了研究卡巴他赛介导的细胞死亡是否由卡巴他赛诱导的ROS生成引起,我们在抗氧化剂NAC存在的情况下处理CRPC细胞。NAC降低了卡巴他赛诱导的细胞毒性作用。我们发现,卡巴他赛可显著抑制Sestrin-3()介导的ROS清除,但多西他赛无此作用。这些结果表明,与多西他赛相比,人类CRPC对卡巴他赛的更高敏感性涉及通过抑制抗氧化酶SESN3的表达来产生ROS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/49333151a587/oncotarget-08-87675-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/f53f2868bbdc/oncotarget-08-87675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/dac85ab0902a/oncotarget-08-87675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/4d6be55f35a0/oncotarget-08-87675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/49333151a587/oncotarget-08-87675-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/f53f2868bbdc/oncotarget-08-87675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/dac85ab0902a/oncotarget-08-87675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/4d6be55f35a0/oncotarget-08-87675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb0/5675663/49333151a587/oncotarget-08-87675-g004.jpg

相似文献

1
Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.卡巴他赛通过抑制去势抵抗性前列腺癌中的Sestrin-3诱导活性氧生成
Oncotarget. 2017 Sep 21;8(50):87675-87683. doi: 10.18632/oncotarget.21147. eCollection 2017 Oct 20.
2
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.新一代紫杉烷类药物的新作用有益于前列腺癌晚期。
Clin Cancer Res. 2015 Feb 15;21(4):795-807. doi: 10.1158/1078-0432.CCR-14-1358.
3
Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.血清外泌体P-糖蛋白是诊断多西他赛耐药性及为前列腺癌患者选择紫杉烷类药物的潜在标志物。
Urol Oncol. 2015 Sep;33(9):385.e15-20. doi: 10.1016/j.urolonc.2015.04.019. Epub 2015 May 28.
4
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.雄激素受体的利用克服晚期前列腺癌中的紫杉烷耐药性。
Adv Cancer Res. 2015;127:123-58. doi: 10.1016/bs.acr.2015.03.001. Epub 2015 Mar 29.
5
ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.ABCB1 介导晚期前列腺癌中 cabazitaxel-docetaxel 的交叉耐药性。
Mol Cancer Ther. 2017 Oct;16(10):2257-2266. doi: 10.1158/1535-7163.MCT-17-0179. Epub 2017 Jul 11.
6
Preclinical profile of cabazitaxel.卡巴他赛的临床前概况。
Drug Des Devel Ther. 2014 Oct 13;8:1851-67. doi: 10.2147/DDDT.S64940. eCollection 2014.
7
Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel.探索高尔基体相关蛋白8B(GOLGA8B)对前列腺癌进展及去势抵抗性前列腺癌对卡巴他赛耐药性的影响。
Discov Oncol. 2024 May 10;15(1):152. doi: 10.1007/s12672-024-00973-7.
8
Practical guide to the use of chemotherapy in castration resistant prostate cancer.去势抵抗性前列腺癌化疗应用实用指南
Can J Urol. 2014 Apr;21(2 Supp 1):77-83.
9
Cabazitaxel exhibits more favorable molecular changes compared to other taxanes in androgen-independent prostate cancer cells.与其他紫杉烷类药物相比,卡巴他赛在雄激素非依赖性前列腺癌细胞中表现出更有利的分子变化。
J Biochem Mol Toxicol. 2020 Sep;34(9):e22542. doi: 10.1002/jbt.22542. Epub 2020 Jun 24.
10
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.卡巴他赛在多西他赛治疗失败的激素难治性前列腺癌患者中的安全性和疗效。
Clin Med Insights Oncol. 2013;7:1-12. doi: 10.4137/CMO.S7256. Epub 2012 Dec 20.

引用本文的文献

1
Combinatorial Effects of Free and Nanoencapsulated Forms of Cabazitaxel and RAS-Selective Lethal 3 in Breast Cancer Cells.卡巴他赛游离形式与纳米包封形式以及RAS选择性致死因子3在乳腺癌细胞中的联合效应
Pharmaceutics. 2025 May 17;17(5):657. doi: 10.3390/pharmaceutics17050657.
2
Sestrins in Carcinogenesis-The Firefighters That Sometimes Stoke the Fire.硒蛋白在致癌作用中的角色——有时煽风点火的消防员。
Cancers (Basel). 2025 May 6;17(9):1578. doi: 10.3390/cancers17091578.
3
Therapeutic efficacy to dose-dependent toxicity of Cabazitaxel in C6-induced glioblastoma model of rats.

本文引用的文献

1
Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.烟酰胺N-甲基转移酶通过抑制ASK1-p38丝裂原活化蛋白激酶途径增强结肠癌细胞对5-氟尿嘧啶的抗性。
Oncotarget. 2016 Jul 19;7(29):45837-45848. doi: 10.18632/oncotarget.9962.
2
Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation.异莲心碱通过产生活性氧和激活p38丝裂原活化蛋白激酶/应激活化蛋白激酶诱导三阴性人乳腺癌细胞凋亡。
Sci Rep. 2015 Jul 29;5:12579. doi: 10.1038/srep12579.
3
Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
卡巴他赛在大鼠C6诱导的胶质母细胞瘤模型中的治疗效果与剂量依赖性毒性
Toxicol Res (Camb). 2025 Apr 2;14(2):tfaf048. doi: 10.1093/toxres/tfaf048. eCollection 2025 Apr.
4
Synergistic Anti-tumorigenic Effects of Cabazitaxel and Usnic Acid Combination on Metastatic Castration-Resistant Prostate Cancer Cells.卡巴他赛与松萝酸联合应用对转移性去势抵抗性前列腺癌细胞的协同抗肿瘤作用
Anticancer Agents Med Chem. 2025;25(9):610-619. doi: 10.2174/0118715206336754241015062614.
5
PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer.PSMA 靶向联合溴结构域抑制剂和多西他赛纳米治疗药物治疗前列腺癌。
Biomed Pharmacother. 2024 Aug;177:117125. doi: 10.1016/j.biopha.2024.117125. Epub 2024 Jul 14.
6
Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes.卡巴他赛的凋亡作用与其在具有不同耐药表型的前列腺癌细胞中的促氧化功效之间的关联。
Cancer Biol Ther. 2024 Dec 31;25(1):2329368. doi: 10.1080/15384047.2024.2329368. Epub 2024 Mar 14.
7
Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy.针对前列腺肿瘤低分子量酪氨酸磷酸酶的氧化增敏治疗。
Sci Adv. 2024 Feb 2;10(5):eadg7887. doi: 10.1126/sciadv.adg7887. Epub 2024 Jan 31.
8
Association between the antioxidant properties of SESN proteins and anti-cancer therapies.SESN 蛋白的抗氧化特性与癌症疗法之间的关联。
Amino Acids. 2023 Jul;55(7):835-851. doi: 10.1007/s00726-023-03281-6. Epub 2023 Jun 7.
9
2-Hydroxyoleic Acid as a Self-Assembly Inducer for Anti-Cancer Drug-Centered Nanoparticles.2-羟基油酸作为以抗癌药物为核心的纳米颗粒的自组装诱导剂
Pharmaceuticals (Basel). 2023 May 9;16(5):722. doi: 10.3390/ph16050722.
10
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.STEAP1 敲低降低前列腺癌细胞对紫杉醇、多西他赛和卡巴他赛的敏感性。
Int J Mol Sci. 2023 Apr 2;24(7):6643. doi: 10.3390/ijms24076643.
青蒿琥酯可诱导活性氧(ROS)和p38丝裂原活化蛋白激酶(p38 MAPK)介导的细胞凋亡,并在体内抑制胚胎性横纹肌肉瘤细胞的肿瘤生长。
Carcinogenesis. 2015 Sep;36(9):1071-83. doi: 10.1093/carcin/bgv098. Epub 2015 Jul 7.
4
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.用拉帕替尼抑制HER2-YB1-AR轴可协同增强恩杂鲁胺在去势抵抗性前列腺癌中的抗肿瘤疗效。
Oncotarget. 2015 Apr 20;6(11):9086-98. doi: 10.18632/oncotarget.3602.
5
Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.活性氧介导的胶质母细胞瘤治疗反应和耐药性。
Cell Death Dis. 2015 Jan 15;6(1):e1601. doi: 10.1038/cddis.2014.566.
6
Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.干扰素诱导的抗病毒蛋白MxA与前列腺癌呈负相关,并调节细胞周期、侵袭以及多西他赛诱导的细胞凋亡。
Prostate. 2015 Feb 15;75(3):266-79. doi: 10.1002/pros.22912. Epub 2014 Oct 18.
7
LKB1 reduces ROS-mediated cell damage via activation of p38.LKB1通过激活p38减少活性氧介导的细胞损伤。
Oncogene. 2015 Jul;34(29):3848-59. doi: 10.1038/onc.2014.315. Epub 2014 Sep 29.
8
Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.双重 PI3K/mTOR 抑制剂 NVP-BEZ235 增敏多西他赛治疗去势抵抗性前列腺癌。
J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.
9
Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.紫杉醇耐药与前列腺癌去势抵抗的相互作用:Twist1、YB-1 和雄激素受体的影响。
Prostate. 2013 Sep;73(12):1336-44. doi: 10.1002/pros.22681. Epub 2013 Jun 14.
10
Cancer statistics, 2013.癌症统计数据,2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.